XORTX Ties Board Shake-Up to Financing Ahead of March 24 Shareholder Vote
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from XORTX Therapeutics Inc ( (TSE:XRTX) ).
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical developer of therapies targeting gout and kidney-related diseases, is advancing drug candidates that inhibit uric acid production by modulating purine metabolism and xanthine oxidase. The company’s portfolio is aimed at improving outcomes in conditions such as gout, ADPKD, acute kidney injury tied to respiratory infections, and Type 2 diabetic nephropathy.
On March 18, 2026, XORTX announced it will propose three substitute director nominees at its March 24, 2026 annual and special shareholder meeting, replacing three previously nominated directors. The board changes are a condition of a significant financing under negotiation, with the new nominees expected to resign if the financing does not close, underscoring how governance adjustments are being used to secure capital subject to TSX Venture Exchange approval.
The new nominees are executives George Scorsis, a veteran of regulated pharmaceutical and consumer sectors; Richard Grieve, an operations and finance leader in media production; and investment professional Mika Grasso, none of whom currently hold XORTX securities or have been compensated by the company. Shareholders, who received meeting materials on March 2, 2026, are being urged by the unanimously supportive board to vote in favour of all resolutions ahead of the March 20, 2026 proxy deadline, as the outcome could influence XORTX’s financing capacity and strategic direction.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.61 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease. Its pipeline includes three clinically advanced candidates: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney and organ injury linked to respiratory virus infections, along with preclinical program XRx-225 for Type 2 diabetic nephropathy.
Average Trading Volume: 7,546
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.46M
Find detailed analytics on XRTX stock on TipRanks’ Stock Analysis page.
